GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Retained Earnings

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Retained Earnings : HK$3,847 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Shenzhen Hepalink Pharmaceutical Group Co's retained earnings for the quarter that ended in Mar. 2024 was HK$3,847 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly retained earnings declined from Sep. 2023 (HK$4,626 Mil) to Dec. 2023 (HK$3,703 Mil) but then increased from Dec. 2023 (HK$3,703 Mil) to Mar. 2024 (HK$3,847 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual retained earnings increased from Dec. 2021 (HK$4,466 Mil) to Dec. 2022 (HK$4,820 Mil) but then declined from Dec. 2022 (HK$4,820 Mil) to Dec. 2023 (HK$3,703 Mil).


Shenzhen Hepalink Pharmaceutical Group Co Retained Earnings Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Retained Earnings Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,204.46 4,356.36 4,465.59 4,819.67 3,703.48

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,991.62 4,695.11 4,625.91 3,703.48 3,846.58

Shenzhen Hepalink Pharmaceutical Group Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Shenzhen Hepalink Pharmaceutical Group Co  (HKSE:09989) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Business Description

Traded in Other Exchanges
Address
No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business and Others. Geographical presence of company is in Hong Kong, United States of America, Europe, Mainland China and Other countries. Majority of the company's revenue comes from USA and Europe.
Executives
Orbimed Capital Llc 2102 Investment manager
Morgan Stanley & Co. International Plc 2105 Underwriter
Morgan Stanley International Holdings Inc. 2201 Interest of corporation controlled by you
Morgan Stanley International Limited 2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk) 2201 Interest of corporation controlled by you
Avict Global Holdings Limited 2101 Beneficial owner
Worldwide Healthcare Trust Plc 2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Headlines

No Headlines